ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0631

Impact of Baseline Proteinuria Level on Long-term Outcomes in Lupus Nephritis
Abstract Number: 2209

Impact of Common Infections on Medication Interruptions, Quality of Life, and Disease Flares in Patients with Rheumatoid Arthritis
Abstract Number: 1146

Impact of COVID-19 on Myositis Testing Trends
Abstract Number: 1437

Impact of Early Diagnosis in Patients with Axial Spondyloarthritis on Arterial Stiffness Progression
Abstract Number: 1124

Impact of Genetic Predisposition for Type 2 Diabetes in Plasma Glucose Levels After the Administration of a High Dose of Systemic Glucocorticoids
Abstract Number: 2148

Impact of Hip Fractures in the Elderly Population: Functional Status, Readmission, and One-Year Mortality
Abstract Number: 0664

Impact of Hydroxychloroquine and Belimumab on Early Glucocorticoid Reduction in New-Onset Systemic Lupus Erythematosus: A Retrospective Analysis of Risk and Protective Factors
Abstract Number: 2429

Impact of Hydroxychloroquine Level on ECG QTC Interval in Patients with Rheumatic Systemic Autoimmune Diseases: A Real-life Study
Abstract Number: 1319

Impact of Illness Cognition and Self-Esteem on Quality of Life in Reproductive-Age Women with Autoimmune Rheumatic Diseases
Abstract Number: 2144

Impact of Immunogenicity on Clinical Outcomes in Postmenopausal Women with Osteoporosis: Results from a Randomized Controlled Phase 3 Study to Compare CT-P41 (Proposed Denosumab Biosimilar) and Reference Denosumab
Abstract Number: 1582

Impact of Immunosuppressive Treatment on Development and Survival in Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Abstract Number: 2653

Impact of Insurance on Time to Biological Drug (bDMARD) Initiation and Inactive Disease Achievement in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 0653

Impact of Lupus Nephritis on Neuropsychiatric SLE Outcomes
Abstract Number: 1360

Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment
Abstract Number: 1611

Impact of Mepolizumab on Patient-reported Outcomes in Eosinophilic Granulomatosis with Polyangiitis by Using the ANCA-associated Vasculitis Patient-reported Outcomes (AAV-PRO) Questionnaire: A European Multicentre Prospective Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].